Dr Reddy’s Lab shares jump over 4% after Russia COVID-19 vaccine Sputnik V agreement

Dr Reddy's Lab shares jump over 4% after Russia COVID-19 vaccine Sputnik V agreement
Image Source : FILE

Dr Reddy’s Lab shares jump over 4% after Russia COVID-19 vaccine Sputnik V agreement

Shares of Dr Reddy’s Laboratories gained over Four per cent on Wednesday after the corporate and Russia’s sovereign wealth fund RDIF agreed to produce 100 million (10 crore) doses of Sputnik V COVID-19 vaccine to the drug maker upon getting regulatory approval in India.

The inventory jumped 4.24 per cent to shut at Rs 4,631.55 on the BSE. During the day, it rose by 4.69 per cent to Rs 4,651.95.

On the NSE, it closed 4.17 per cent larger at Rs 4,442.35.

The Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories have agreed to cooperate on scientific trials and distribution of Sputnik V vaccine in India, RDIF and Dr Reddy’s stated in a joint assertion.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and have become the world’s first registered vaccine in opposition to COVID-19 based mostly on the human adenoviral vectors platform.

Deliveries may doubtlessly start in late 2020 topic to completion of profitable trials and registration of the vaccine by regulatory authorities in India, the assertion added.

The assertion, nonetheless, didn’t present any monetary particulars of the agreement between the companions.

The Sputnik V vaccine is present process scientific trials for the coronavirus pandemic, it stated.

“We are very pleased to partner with Dr. Reddy’s in India… India is amongst most severely impacted countries from COVID-19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID 19,” RDIF CEO Kirill Dmitriev stated.

Dr Reddy’s Laboratories Co-Chairman and MD G V Prasad stated that the corporate is happy to associate with RDIF to carry the vaccine to India. The Phase I and II scientific trials have proven promising outcomes.

“We will be conducting Phase-III trials in India to ensure safety and efficacy for the Indian population and to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India,” he added. 

Latest Business News

Fight against Coronavirus: Full coverage

Source link


About The Author